ATE311464T1 - Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen - Google Patents

Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen

Info

Publication number
ATE311464T1
ATE311464T1 AT01956747T AT01956747T ATE311464T1 AT E311464 T1 ATE311464 T1 AT E311464T1 AT 01956747 T AT01956747 T AT 01956747T AT 01956747 T AT01956747 T AT 01956747T AT E311464 T1 ATE311464 T1 AT E311464T1
Authority
AT
Austria
Prior art keywords
cell
therapeutic
activated receptors
diagnostic uses
targeting
Prior art date
Application number
AT01956747T
Other languages
English (en)
Inventor
Ofer Mandelboim
Angel Porgador
Original Assignee
Yissum Res Dev Co
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Univ Ben Gurion filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE311464T1 publication Critical patent/ATE311464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT01956747T 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen ATE311464T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13741900A IL137419A0 (en) 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses
PCT/IL2001/000664 WO2002008287A2 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses

Publications (1)

Publication Number Publication Date
ATE311464T1 true ATE311464T1 (de) 2005-12-15

Family

ID=11074420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01956747T ATE311464T1 (de) 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen

Country Status (9)

Country Link
US (1) US20040072256A1 (de)
EP (1) EP1301605B1 (de)
JP (1) JP2004504065A (de)
AT (1) ATE311464T1 (de)
AU (2) AU2001278662B2 (de)
CA (1) CA2416733A1 (de)
DE (1) DE60115452D1 (de)
IL (1) IL137419A0 (de)
WO (1) WO2002008287A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003051834A2 (en) * 2001-12-14 2003-06-26 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
AU2003295401B2 (en) * 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
CA2509400A1 (en) * 2002-12-09 2004-06-24 Natspears Ltd. Nk cell receptor conjugates for treating malignancies
EP1445614A1 (de) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Überwachung der Entwicklung von HIV Virus eines Individuums
GB0305478D0 (en) * 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
US7825085B2 (en) 2003-06-30 2010-11-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
WO2005051973A2 (en) * 2003-11-25 2005-06-09 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Peptides derived from natural cytotoxicity receptors and methods of use thereof
CN1954217B (zh) * 2004-02-06 2013-05-08 国立健康与医学研究所 衍生自gp41的多肽、含有所述多肽的疫苗组合物以及用于治疗个体HIV病毒感染的用途
EP1861500A2 (de) * 2005-03-18 2007-12-05 Innate Pharma Expressionsvektoren und methoden zur erzielung einer nk-zell-spezifischen expression
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2009147137A1 (en) * 2008-06-02 2009-12-10 Institut Gustave Roussy NATURAL KILLER p30 (NKp30) DYSFUNCTION AND THE BIOLOGICAL APPLICATIONS THEREOF
US8420092B2 (en) 2009-03-19 2013-04-16 Ben-Gurion University Of The Negev Research And Development Authority Method of treating diabetes by administering an anti-NKp46 antibody
EP2723362A1 (de) 2011-06-21 2014-04-30 Innate Pharma Nkp46-vermittelte nk-zellenabstimmung
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
WO2015110831A1 (en) 2014-01-24 2015-07-30 University Court Of The University Of St Andrews Immunomodulatory compounds
JP7082604B2 (ja) * 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
EP3481412A4 (de) 2016-07-11 2020-03-18 The National Institute for Biotechnology in the Negev, Ltd. Fusionsproteine mit verlängerter serumhalbwertszeit
GB201616009D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Treatment and/or prevention of sepsis
GB201616007D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Novel Adjuvants
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2022230011A1 (en) * 2021-03-05 2023-10-19 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Antibody against nkp46 and application of antibody
CN117304342B (zh) * 2023-09-28 2024-07-19 上海恩凯细胞技术有限公司 嵌合抗原受体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
JP4170390B2 (ja) * 1995-02-24 2008-10-22 ザ ジェネラル ホスピタル コーポレーション 受容体キメラによる細胞性免疫の再指示
CA2217020A1 (en) * 1995-05-16 1996-11-21 Bristol-Myers Squibb Company Recombinant heregulins and their biological functions upon receptor activation
WO1999023867A2 (en) * 1997-11-07 1999-05-20 Biogen, Inc. Bmog, a protein member of the myelin-oligodendrocyte glycoprotein family and its use

Also Published As

Publication number Publication date
EP1301605B1 (de) 2005-11-30
DE60115452D1 (de) 2006-01-05
CA2416733A1 (en) 2002-01-31
WO2002008287A2 (en) 2002-01-31
JP2004504065A (ja) 2004-02-12
EP1301605A2 (de) 2003-04-16
US20040072256A1 (en) 2004-04-15
WO2002008287A3 (en) 2002-12-19
IL137419A0 (en) 2001-07-24
AU7866201A (en) 2002-02-05
AU2001278662B2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DE60115452D1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
ES2562651T3 (es) Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
UY29504A1 (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
ATE442379T1 (de) Bildgebende agentien auf basis bizyklischer peptide
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
DE60032486D1 (de) Prion protein peptide und deren verwendung
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
NO20024932D0 (no) Kontrastmiddel
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
ATE398630T1 (de) Zyklische conotoxin-peptide
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
CY1105942T1 (el) Sgk3 ως διαγνωστικος και θepαπευτικος στοχος
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
MX2009001014A (es) Mediacion de citotoxicidad de celulas que evidencian expresion de cd63 en superficie.
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
BR112022016986A2 (pt) Peptídeos cíclicos e seus conjugados para endereçar alfa-v-beta-6-integrina in vivo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties